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H I G H L I G H T S
• There is a mismatch in clinical and genetic familial hypercholesterolemia diagnosis.
• Familial hypercholesterolemia is a syndrome including several entities.
• Monogenic and polygenic familial hypercholesterolemia determines high vascular risk.
• Familial hypercholesterolemia diagnosis has implications to access new therapies.
• A new classification including all FH genotypes and phenotypes is warranted.
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A B S T R A C T
The introduction of singular therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i),
to lower high cholesterol levels requires better classification of patients eligible for intensive lipid lowering
therapy. According to the European Medicines Administration, PCSK9i are recommended in primary prevention
in familial hypercholesterolemia (FH) patients. Therefore, an FH diagnosis is not simply an academic issue,
because it has many clinical implications. The bases of a diagnosis of FH are not entirely clear. The availability of
genetic testing, including large genome-wide association analyses and whole genome studies, has shown that
some patients with a clinical diagnosis of definite FH have no mutations in the genes associated with the disease.
This fact does not exclude the very high cardiovascular risk of these patients, and an early and intensive lipid
lowering therapy is recommended in all FH patients. Because an FH diagnosis is a cornerstone for decisions
about therapies, a precise definition of FH is urgently required.
This is an expert consensus document from the Spanish Atherosclerosis Society.
We propose the following classification: familial hypercholesterolemia syndrome integrated by (1) hetero-
zygous familial hypercholesterolemia: patients with clinically definite FH and a functional mutation in one allele
of the LDLR, ApoB:100, and PCSK9 genes; (2) homozygous familial hypercholesterolemia: mutations affect both
alleles; (3) polygenic familial hypercholesterolemia: patients with clinically definite FH but no mutations as-
sociated with FH are found (to be distinguished from non-familial, multifactorial hypercholesterolemia); (4)
familial hypercholesterolemia combined with hypertriglyceridemia: a subgroup of familial combined hyperli-
pidaemia patients fulfilling clinically definite FH with associated hypertriglyceridemia.
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1. Introduction
The bases for the diagnosis of familial hypercholesterolemia (FH)
are not entirely clear. Until a few years ago, only clinical criteria were
used, and this continues to be the only diagnostic method in many
places. By definition, FH is a genetic condition; however, in many pa-
tients fulfilling the clinical criteria for definite FH, a causative genetic
alteration cannot be found; on the other hand, patients with genetic
mutations in the FH associated genes lack the expected phenotype [1].
This mismatch can range from 10% to 50% of all FH patients. Data from
whole genome analyses suggest that any undiscovered gene could ex-
plain the disease in these patients. A more plausible explanation is that
these families have a polygenic form of FH [2]. Furthermore, the clin-
ical phenotype is highly variable among FH patients, even in those
sharing the same pathogenic mutation, which suggests that FH is a
complex syndrome rather than a single disease. The association be-
tween FH and cardiovascular risk was established before the genetic era
and has been built on the basis of clinical diagnosis. Therefore, ac-
cording to the latest clinical guidelines, in all FH patients, early and
intensive lipid lowering therapy (LLT) should be considered [3,4]. This
concept is essential considering the eruption of proprotein convertase
subtilisin/kexin type 9 inhibitors (PCSK9i) in the treatment plans. Ac-
cording to the European Medicines Administration, PCSK9i should be
prescribed for patients with a previous major cardiovascular event and
for FH patients, even as primary prevention, if they continue to have
uncontrolled LDL levels after optimal LLT. Due to treatment costs,
guidelines for defining the patients eligible for PCSK9i are strict and an
FH diagnosis is a cornerstone for deciding on therapy [5,6].
Therefore, the FH diagnosis is not simply an academic issue but has
many clinical implications. Because a precise definition of FH is ur-
gently required, we propose the following classification system.
2. Familial hypercholesterolemia syndrome
The term “syndrome” (from the Greek “running together”) is ap-
plied to a group of signs and symptoms occurring together to char-
acterize a particular condition or phenotype. This condition can have
different aetiologies, or its origin can be poorly understood.
Considering that FH is a clinical presentation characterized by very
high LDL cholesterol levels with explicit familial aggregation and
transmission, high cardiovascular risk and different causes, the use of
the term FH syndrome is warranted. The FH syndrome includes ge-
netically and clinically defined FH according the following entities
(Table 1):
2.1. Heterozygous familial hypercholesterolemia (HFH)
HFH is the monogenic disease characterized by high LDL con-
centrations from birth, autosomal co-dominant heritage, presence of
corneal arcus or tendon xanthomas in some patients, family history of
premature cardiovascular disease and a single functional mutation in
one allele of any of the following genes: LDLR, APOB, or PCSK94,6.
Occasionally, rare variants in genes such as APOE, signal transdu-
cing adaptor protein family 1 (STAP1) and patatin-like phospholipase-
domain-containing family (PNPLA5) can also cause a heterozygous FH
phenotype [7].
The diagnostic requirement is the presence of a functional mutation
in one of the abovementioned genes.
2.2. Homozygous familial hypercholesterolemia (HoFH)
HoFH is the severe form of the previous disease [8]. Cardiovascular
complications, including aortic valve and coronary heart disease, ap-
pear before the age of twenty years. This condition can be classified as:
• Real homozygous: when the same mutation affects both alleles of Ta
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one of the major FH-related genes (LDLR, ApoB, or PCSK9).
• Compound heterozygous: when different mutations affect two al-
leles of one of the major FH-associated genes.
• Combined heterozygous: when different mutations affect two dif-
ferent FH-related genes.
• Autosomal recessive hypercholesterolemia (ARH). This condition
presents with the same HoFH phenotype; however, it is transmitted
as an autosomal-recessive disease. Therefore, the parents of the af-
fected child have normal LDL concentrations. These patients have
both LDLR adaptor protein 1 (LDLRAP1) gene alleles affected. The
severity of the illness falls between the other HoFH forms, and a
better response to statins has been observed [9].
2.3. Polygenic familial hypercholesterolemia (PFH)
PFH includes patients with a definite FH diagnosis (according to
Simon Broom (SB), Dutch Lipid Clinics Network (DLCN), World Health
Organization (WHO) indexes or others), but monogenic alterations as-
sociated with FH are not found. PFH accounts for 10–50% of all clini-
cally definite FH patients depending on the clinical setting [1,10].
These families usually have several members with very high cho-
lesterol levels (LDL above 5 mmol/L) suggesting vertical transmission,
some with tendon xanthomas or corneal arcus, and a high burden of
cardiovascular disease, thereby fulfilling the FH clinical criteria.
An extensive search for alternative candidate genes to explain this
lipid disorder, including whole exome sequencing, yielded no new
mutations [11].
Several lines of evidence show that these patients have a polygenic
form of hypercholesterolemia since they carry a high number of gene
variants associated with high LDL levels [2,12] and/or major genetic
determinants of high cholesterol levels such as apo E4.
These patients have a high cardiovascular risk because they have a
genetically driven high LDL-C concentration, sometimes observed from
a young age. Although the risk is probably lower than that of geneti-
cally proven heterozygous FH, according to recent data [13], these
patients must be managed clinically and treated as FH according to
international guidelines [1,3].
The diagnostic requirement is a definite FH classification according
any of the abovementioned clinical indexes (the yield of either DLCN or
SB indexes is similar [10]), despite negative genetic testing. If available,
an LDL cholesterol genetic risk score can help to support the diagnosis
[12], although it is not formally recommended.
The term PFH must be differentiated from Polygenic
Hypercholesterolemia. The latter has been broadly used to define pa-
tients with high cholesterol, usually with lower concentrations than
those of FH patients, and generally without family aggregation.
Polygenic Hypercholesterolemia is by far the most frequent cause of
hypercholesterolemia; however, its pathophysiology is not fully un-
derstood. Both increased apoB-LDL production and reduced fractional
catabolic rates have been observed [14]. Polygenic Hypercholester-
olemia is considered to be the product of a polygenic and environment
interaction. Therefore, we suggest using the term “Multifactorial Hy-
percholesterolemia” instead of “polygenic” to avoid confusion.
2.4. Familial hypercholesterolemia combined with hypertriglyceridemia
(FHcTG)
Familial combined hyperlipidaemia (FCH) was described by
Goldstein et al. as a highly prevalent inherited metabolic disorder
characterized by both high cholesterol and triglycerides with a variable
phenotype [15]. The presence of tendon xanthomas or corneal arcus
has also been reported. These patients have a very high cardiovascular
risk, and the genetic transmission again suggests an autosomal-domi-
nant pattern. However, after decades of an intense search for the causal
gene or genes, none has been detected to date, and FCH is currently
considered a polygenic disease.
These families carry a collection of genes causing high cholesterol
and another set determining high triglycerides [16,17]. Since the hy-
percholesterolemic component in some families cannot be dis-
tinguished from that of the abovementioned polygenic FH, these fa-
milies should also be considered as having the FH syndrome. According
to the Spanish Arteriosclerosis Society registry, approximately 10–20%
of clinically definite FH patients have high triglycerides. In fact, ap-
proximately 1 in 5 patients classified as FCH have LDLRmutations [18].
We propose the term FHcTG to designate a subgroup of FCH patients
fulfilling FH criteria; therefore, including patients with very high cho-
lesterol levels (LDL above 5 mmol/L) despite concomitant high tri-
glyceride levels.
The diagnostic requirement for this category is to fulfil the diag-
nostic criteria for definite clinical FH according to the SB, DLCN, and
WHO indexes or others, despite high triglycerides and negative genetic
testing.
3. Conclusions
The intense and differential management of FH, including the in-
troduction of singular therapies such as PCSK9i to lower high choles-
terol levels, demands a better definition of this concept. This definition
should not exclude patients with severe hypercholesterolemia and fa-
milial aggregation because we are not able, at this time, to diagnose the
cause of their metabolic defect. On the other hand, the availability of
genetic testing, including large genome-wide association analyses and
whole genome studies, has shown that about one in three patients with
a clinical diagnosis of definite FH have no mutations in the genes as-
sociated with the disease. This fact does not exclude the very high
cardiovascular risk of these FH patients with negative genetic tests.
Data from extensive genetic studies suggest that there are no hidden
genes accounting for this condition. These affected families probably
carry a collection of gene variants giving rise to high cholesterol levels.
A different aetiology is no reason to exclude these patients from ef-
fective therapies aimed at genetically caused hypercholesterolemia.
On the other hand, classical FCH is currently considered a polygenic
disease, with the concurrence of a set of gene variants associated with
hypercholesterolemia and another associated with hypertriglycer-
idemia. There is no reason to exclude FCH patients when hypercho-
lesterolemia is severe and constant from highly efficient therapies
simply because they, or their family members, also have high trigly-
cerides.
The term Familial Hypercholesterolemia Syndrome includes all
these different conditions characterized by high cholesterol levels, fa-
mily aggregation, a genetic cause, and increased cardiovascular risk.
We are not challenging the FH definition, screening pathways nor
clinical management recommendations. Our aim is to help clinicians to
properly classify FH patients by providing a clear-cut definition of
various clinical conditions.
The novelty of this classification will probably open up the debate
and the exchanges of opinion that we would like to result in a better
definition of the relevant individual categories within the framework of
familial hypercholesterolemia.
We consider that an official statement on the definition of FH will
have an important impact on both physicians and health authorities
when designing ASCVD prevention strategies.
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